Francesca Bagnato
Vanderbilt University Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Francesca Bagnato as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:29 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05177718 · Natalizumab and Chronic InflammationVanderbilt University Medical Center · terminated · Multiple Sclerosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:29 UTC. The ranking covers the 200 most relevant of 12 PubMed records, and a shared surname and initials can bring in a namesake. All 12 on PubMed
- Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis.J Neurol · 200268 citationsRCR 1.7
- Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease.Ann Neurol · 200552 citationsRCR 1.4
- 49 citationsRCR 1.5
- Heterogeneity of Multiple Sclerosis White Matter Lesions Detected With T2*-Weighted Imaging at 7.0 Tesla.J Neuroimaging · 201533 citationsRCR 1.4
- Isosorbide dinitrate or nifedipine: which is preferable in the medical therapy of achalasia?Ital J Gastroenterol · 199426 citationsRCR 1.2
- Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.Arch Neurol · 200522 citationsRCR 0.5
- Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies.J Neurol · 200720 citationsRCR 0.6
- Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.Arch Neurol · 200918 citationsRCR 0.5
- 17 citationsRCR 0.5
- Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis.Mult Scler · 199812 citationsRCR 0.4